Clinical Endpoint– tag –
-
AbbVie’s Etentamig: A Next-Generation Bispecific Engager Set to Redefine Multiple Myeloma Treatment
Fierce Biotech USA Overview AbbVie has announced positive Phase 3 clinical trial results for etentamig, a second-generation bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM). Targeting BCMA and CD3, ... -
BioRay Pharmaceutical Advances Novel Dual-Payload TROP2 ADC, BR113, into First-in-Human Clinical Trials
AllSci China Overview China's BioRay Pharmaceutical has initiated a first-in-human Phase I trial for BR113, an innovative dual-payload TROP2 antibody-drug conjugate (ADC) targeting patients with advanced solid tumors. BR113 distinguishes... -
Revolutionizing TNBC Treatment: Datroway ADC Gains EU Nod for Immunotherapy-Ineligible Patients
Precision Medicine Online European Union Overview AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has received European Commission approval as a first-line monotherapy for patients with ... -
Roche’s Cevostamab Achieves 42.1% ORR in Phase 1 for Relapsed/Refractory Multiple Myeloma
OncLive USA Overview Roche's investigational FcRH5 x CD3 bispecific antibody cevostamab (RG6160) demonstrated an overall response rate (ORR) of 42.1% across all dose levels (n=324) in a Phase 1 trial for relapsed/refractory multiple myel... -
First-in-Class EGFR-HER3 Bispecific ADC Iza-Bren Achieves 48.1% ORR in Phase Ib for Extensive-Stage Small Cell Lung Cancer
ASCO Publications USA Overview Results from a Phase Ib study of Izalontamab Brengitecan (Iza-Bren), the first-in-class EGFR-HER3 bispecific antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (SCLC), have been announ... -
Daiichi Sankyo & AstraZeneca’s Enhertu Plus Pertuzumab Recommended for EU Approval as 1st-Line Treatment for HER2-Positive Metastatic Breast Cancer, Achieves 44% Risk Reduction in Phase III
Daiichi Sankyo Press Release Japan Overview The EMA's CHMP has recommended Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for approval as a first-line treatment for HER2-positive metastatic breast cancer in the EU. This ... -
FDA Approves First PROTAC Vepdegestrant (ARV-471) for ER+/HER2- Breast Cancer, Ushering in a New Era of Targeted Protein Degradation
Journal of Medicinal Chemistry - ACS Publications USA Overview On May 1, 2026, the FDA approved vepdegestrant (ARV-471; Veppanu), making it the first heterobifunctional PROTAC protein degrader approved for clinical practice. Indicated fo... -
FDA Approves First-in-Class PROTAC Degrader Vepdegestrant for ESR1-Mutated Breast Cancer, Improving Progression-Free Survival by 43%
Dana-Farber Cancer Institute USA Overview The U.S. FDA has approved vepdegestrant (Veppanu), a first-in-class PROTAC (Proteolysis-Targeting Chimera) degrader, for patients with ER-positive, HER2-negative metastatic breast cancer harborin... -
First Oral ER PROTAC Vepdegestrant Gains FDA Approval, Ushering New Era in Targeted Protein Degradation
MDPI Switzerland Overview The field of Targeted Protein Degradation (TPD) marks a significant milestone with the FDA approval of vepdegestrant (VEPPANU, ARV-471), the first oral estrogen receptor (ER) targeted PROTAC, co-developed by Arv... -
FDA Approves Celcuity’s Revtorpyk (gedatolisib) for HR-Positive, HER2-Negative Metastatic Breast Cancer in New Combination Regimen
FDA USA Overview On July 14, 2026, the FDA approved Celcuity Inc.'s Revtorpyk (gedatolisib) for adult patients with HR-positive/HER2-negative metastatic breast cancer without PIK3CA mutation. The drug is approved for use in combination w...
12